修改蜜蜂中弗洛尼卡米德现有的最大残留量
EFSA journal. European Food Safety Authority
|October 16, 2024
概括
对蜂蜜中的弗洛尼卡米德的最大残留量 (MRL) 进行了审查. 目前的MRL是足够的,残留物水平不会对消费者健康构成风险.
科学领域:
- 食品安全 食品安全
- 环境科学 环境科学
- 分析化学 分析化学
背景情况:
- 提交了一份要求修改蜂蜜中弗洛尼卡米德的最大残留量 (MRL).
- 提供的初始数据不足以建立新的MRL提案.
研究的目的:
- 评估蜂蜜中弗洛尼卡米德的现有MRL的充分性.
- 评估蜂蜜中的弗洛尼卡米德残留物对消费者健康的潜在风险.
主要方法:
- 分析来自欧盟监测计划 (2009-2023) 的监测数据.
- 评估植物保护产品在蜂蜜作物上的使用所产生的残留物吸收情况.
- 对残留物执法分析方法的评估.
主要成果:
- 目前的MRL被认为足够用于蜂蜜中的弗洛尼卡米德残留物.
- 在监测数据中观察到的残留物水平不太可能构成健康风险.
- 有足够的分析方法可用于执行.
结论:
- 现有的蜂蜜中弗洛尼卡米德的MRL仍然是适当的.
- 蜂蜜中的弗洛尼卡米德残留物,在观察到的水平上,不会对消费者健康构成风险.
- 通过经过验证的分析方法,强制执行弗洛尼卡米德残留物是可行的.
相关概念视频
Clinically Relevant Drug Product Specifications: Methods of Establishment
300
Product specifications define the acceptable quality of a pharmaceutical product by ensuring identity, purity, potency, and strength. These specifications serve as benchmarks during development, manufacturing, and post-approval quality control. Clinically relevant specifications are particularly important because they directly relate to a drug's safety and efficacy in clinical use.Dissolution studies are critical biopharmaceutic tools that link in vitro behavior to in vivo performance. They...
300
FDA Approved Drugs: Changes to Approved Drugs
343
Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...
343


